Cargando…
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered a group with special susceptibility, particularly...
Autores principales: | Franco, Fernando, Guirado, María, Martínez-Banaclocha, Natividad, Gumà, Josep, Lavernia, Javier, Gómez-Codina, José, Rodriguez-Abreu, Delvys, Martínez, Fani, Barrajón, Enrique, Méndez, Miriam, Calvo, Virginia, Provencio, Mariano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025807/ https://www.ncbi.nlm.nih.gov/pubmed/33809772 http://dx.doi.org/10.3390/curroncol28020118 |
Ejemplares similares
-
SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)
por: Gumà, Josep, et al.
Publicado: (2023) -
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
por: Provencio, Mariano, et al.
Publicado: (2017) -
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
por: Jiménez-Cortegana, Carlos, et al.
Publicado: (2021) -
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
por: Palazón-Carrión, Natalia, et al.
Publicado: (2022) -
SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
por: Rueda Domínguez, A., et al.
Publicado: (2015)